Newsroom
Sorted by: Latest
-
Nathan Simington Joins Ericsson Federal as New Director of Policy & Strategy
VIENNA, Va.--(BUSINESS WIRE)--Ericsson Federal Technologies Group (Ericsson Federal) is proud to announce the appointment of Nathan Simington as Director of Policy & Strategy. Simington brings exceptional expertise and leadership that will strengthen Ericsson Federal’s position in the U.S. Government (USG) and Department of War (DoW) telecommunications and technology sectors. “I am honored to join Ericsson Federal as Director of Policy & Strategy to help accelerate the integration of 5G...
-
Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset
ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for the asset. The asset has been developed internally by PepLib to date. Through this transaction...
-
CD22 Targeted Therapies Market Research Report 2025-2026: Approved Drug Sales, Technology Platforms & Clinical Trials Insights - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: Current & Future Global Market Outlook Insight on CD22 Targeted Approaches Approved Drug Dosage, Price & Sales Insight CD22 Targeted Therapies Development Trends by Region & Indications CD22 Targeted Therapies in Clinical Trials: > 20 Therapies CD22...
-
Resumen: Armis protege al principal proveedor de salud pública de Italia para la ciudad de Nápoles en el marco del aumento de las ciberamenazas
SAN FRANCISCO--(BUSINESS WIRE)--Armis, la empresa de seguridad y gestión de la ciberexposición, anunció hoy que ASL Napoli 1 Centro, el principal proveedor de salud pública de Italia para la ciudad de Nápoles, protegerá su superficie de ataque con Armis Centrix™, la plataforma de gestión de ciberexposición de Armis. Antes de trabajar con Armis, ASL Napoli 1 Centro no contaba con las herramientas ni con las capacidades para monitorizar activos físicos y virtuales en tiempo real, lo que represent...
-
Armis schützt Italiens primären Anbieter öffentlicher Gesundheitsversorgung für die Stadt Neapel vor zunehmenden Cyberbedrohungen
SAN FRANCISCO--(BUSINESS WIRE)--Armis, das Unternehmen für Cyber-Risikomanagement und -Sicherheit, hat heute bekannt gegeben, dass ASL Napoli 1 Centro, Italiens primärer Anbieter öffentlicher Gesundheitsversorgung für die Stadt Neapel, seine Angriffsfläche mit Armis Centrix™ sichert, der Cyber-Exposure-Management-Plattform von Armis. Bevor sich ASL Napoli 1 Centro die Unterstützung von Armis sicherte, hatte es weder die Werkzeuge noch die Fähigkeiten, physische und virtuelle Assets in Echtzeit...
-
Riassunto: Armis protegge il principale ente erogatore di sanità pubblica in Italia per la città di Napoli, mentre aumentano le minacce informatiche
SAN FRANCISCO--(BUSINESS WIRE)--Armis, la società di gestione dell'esposizione e della sicurezza informatica, ha annunciato oggi che ASL Napoli 1 Centro, il principale ente erogatore di sanità pubblica in Italia per la città di Napoli, sta proteggendo la sua superficie di attacco utilizzando Armis Centrix™, la Cyber Exposure Management Platform (Piattaforma di gestione dell'esposizione informatica) di Armis. Prima della collaborazione con Armis, ASL Napoli 1 Centro non aveva né gli strumenti né...
-
Samenvatting: Armis beveiligt de belangrijkste openbare zorgverlener van Italië voor de stad Napels nu cyberdreigingen toenemen
SAN FRANCISCO--(BUSINESS WIRE)--Armis, het bedrijf voor cyberrisicobeheer en -beveiliging, heeft vandaag bekendgemaakt dat ASL Napoli 1 Centro, de belangrijkste openbare zorgverlener voor de stad Napels in Italië, zijn aanvalsoppervlak beveiligt met behulp van Armis Centrix™, het Armis Cyber Exposure Management Platform. Voordat ASL Napoli 1 Centro met Armis ging werken, beschikte het niet over de tools of mogelijkheden om fysieke en virtuele activa in real time te monitoren. Dit vormde een uit...
-
Armis sécurise le principal fournisseur de soins de santé publique de la ville de Naples face à l'augmentation des cybermenaces
SAN FRANCISCO--(BUSINESS WIRE)--Armis, société spécialisée dans la gestion de l'exposition aux cybermenaces et la sécurité, a annoncé aujourd'hui que l' ASL Napoli 1 Centro, principal fournisseur de soins de santé publics de la ville de Naples en Italie, sécurise sa surface d'attaque grâce Armis Centrix™, la plateforme de gestion de l'exposition aux cybermenaces d'Armis. Avant de collaborer avec Armis, l'ASL Napoli 1 Centro ne disposait pas des outils ni des capacités nécessaires pour surveille...
-
Westlake Financial and HFC Acceptance Complete $100 Million Loan Acquisition in Landmark Transaction
LOS ANGELES--(BUSINESS WIRE)--Westlake Financial (“Westlake”), the largest privately held auto finance company, today announced the successful sale of approximately $100 million of subprime auto loans to HFC Acceptance, LLC (“HFC Acceptance”). The transaction, designated WTTD-2026-1 (“Transaction”), represents a first-of-its-kind structure for both organizations and was completed at a 112% principal premium. The transaction consists of seasoned and newly originated subprime auto finance loans o...
-
Vy Spine Announces FDA Clearance for VyBrate VBR System
BOUNTIFUL, Utah--(BUSINESS WIRE)--Vy Spine, a spine innovation leader using differentiated materials and designs, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its VyBrate VBR System which is designed for use in both the cervical and thoracolumbar spine for vertebral body replacement surgery. The VyBrate VBR is an innovative device combining the osseointegration properties of the OXPEKK material and the novel OsteoVy lattice structure...